Total Joint Arthroplasty in Patients Taking Methadone or Suboxone Preoperatively for Prior Heroin Addiction: A Prospective Matched Cohort Study

March 2, 2016

Preoperative narcotic use has been associated with poor outcomes following total joint arthroplasty (TJA). The purpose of this study is to compare clinical outcomes of patients undergoing elective TJA while concurrently being treated with methadone or buprenorphine/naloxone for prior heroin addiction to a matched control group. (Source: The Journal of Arthroplasty)

Read the full article →

Total Joint Arthroplasty in Patients Taking Methadone or Buprenorphine/Naloxone Preoperatively for Prior Heroin Addiction: A Prospective Matched Cohort Study

March 2, 2016

Preoperative narcotic use has been associated with poor outcomes after total joint arthroplasty (TJA). The purpose of this study is to compare clinical outcomes of patients undergoing elective TJA while concurrently being treated with methadone or buprenorphine/naloxone for prior heroin addiction to a matched control group. (Source: The Journal of Arthroplasty) MedWorm Sponsor Message: Directory […]

Read the full article →

Why are doctors writing opioid prescriptions — even after an overdose?

March 2, 2016

A group of researchers at Boston Medical Center recently looked at nearly 3,000 patients who had survived an opioid-related overdose between 2000 and 2012. According to their recently published study, over 90% of these patients continued to receive opioid medications from doctors — even after their overdose. Given the soaring numbers of opioid-related overdose deaths […]

Read the full article →

Management of patients with issues related to opioid safety, efficacy and/or misuse: a case series from an integrated, interdisciplinary clinic.

March 2, 2016

CONCLUSIONS: The core components of our approach-biopsychosocial assessment and multimodal treatment planning with an emphasis on promoting functional goals and safety using clear communication and a patient-centered stance-should guide providers in the management of similar clinical scenarios. More evidence is needed to definitively guide specific interventions and points of clinical equipoise. PMID: 26818474 [PubMed – […]

Read the full article →

Presence or Absence of QTc Prolongation in Buprenorphine-Naloxone Among Youth With Opioid Dependence

March 2, 2016

Objectives: The aim of the study was to evaluate buprenorphine-naloxone effects on the QTc in youth with opioid dependence. Buprenorphine is a partial agonist that is an effective treatment for opioid dependence. Compared with methadone, it has a lower risk of QTc prolongation in adults, but is less studied in the youth. It may also […]

Read the full article →

W-18, a synthetic opiate 100 times more potent than fentanyl

March 2, 2016

W-18 Last August, Canadian police seized 110 illegal fentanyl pills at a home in Alberta province. Yesterday, Global News reported that some of the pills have tested positive for an extremely potent opioid called W-18. This is certainly a disturbing development, since W-18 is a μ-receptor agonist 100 times more potent than fentanyl. According to […]

Read the full article →

Letter Reveals Drug Courts Lobbied Against Key Addiction Treatment

March 2, 2016

WASHINGTON – The head of a nonprofit organization that represents drug courts lobbied the U.S. Department of Health and Human Services against increasing access to a key addiction treatment. In an Aug. 19, 2014, letter obtained by The Huffington Post through an open records request, West Huddleston, the then-CEO of the National Association of Drug Court […]

Read the full article →

Letter Reveals Drug Courts Lobbied Against Key Addiction Treatment

February 12, 2016

WASHINGTON – The head of a nonprofit organization that represents drug courts lobbied the U.S. Department of Health and Human Services against increasing access to a key addiction treatment. In an Aug. 19, 2014, letter obtained by The Huffington Post through an open records request, West Huddleston, the then-CEO of the National Association of Drug Court […]

Read the full article →

Akorn Launches Buprenorphine/Naloxone Sublingual Tablets and Tobramycin Injection

February 8, 2016

LAKE FOREST, Ill., Jan. 19, 2016 — (Healthcare Sales & Marketing Network) — Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that it has launched Buprenorphine and Naloxone Sublingual Tablets CIII in 2mg/0.5mg and 8… Biopharmaceuticals, Generics, Product LaunchAkorn, Buprenorphine, Naloxone, Tobramycin (Source: HSMN NewsFeed)

Read the full article →

Overdose Reversal Drug Now Available To Every U.S. High School Free Of Charge

February 8, 2016

Any high school in the U.S. that wants to carry an emergency opioid overdose reversal kit will now be able to get one free of charge, thanks to a new initiative announced Monday by the Clinton Foundation and the drug’s manufacturer. Adapt Pharma, manufacturers of a nasal-spray form of naloxone, also known as Narcan, has […]

Read the full article →

← Previous Entries

Next Entries →